Small Pharma has had its second United States patent granted by the United States Patent Office.
Cybin has entered into an agreement with Mindset Pharma to acquire an exclusive license to an extensive, targeted class of tryptamine-based molecules.
University of Cincinnati postdoctoral researcher Neşe Devenot has stated that the field of psychedelics is fraught with ethical concerns and financial interests.
Drug discovery and development company Mindset Pharma has filed for national patents protecting “Family 1” – second-generation psilocybin analogues – in 16 different countries, including South...
UK-based Small Pharma has announced that its DMT patent strategy has been strengthened with a new US patent protection on injectable DMT delivery in its lead...
PsiloTec Health Solutions Inc.,
Biotech company Cybin has filed an international patent application related to methods for the delivery of psychedelic medications.
Cybin has filed two international patent applications to support its psychedelic research phases programmes.